Boston Scientific Reports Strong Q1 Results, Meets EPS Guidance, and Updates Full-Year Outlook

summarizeSummary

Boston Scientific reported Q1 results that met the high end of adjusted EPS guidance, provided updated full-year and new Q2 outlooks, and announced several positive product development and M&A updates.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported net sales of $5.203 billion, an 11.6% increase, and adjusted EPS of $0.80, which met the high end of the company's guidance range of $0.78 to $0.80 per share.

• Updated Full-Year and Q2 Guidance

  Revised full-year 2026 net sales growth to 7.0-8.5% (reported) and adjusted EPS to $3.34-$3.41. For Q2 2026, the company projects net sales growth of 5.5-7.5% (reported) and adjusted EPS of $0.82-$0.84.

• Positive Clinical Trial Results

  Announced favorable outcomes from the CHAMPION-AF, HI-PEITHO, and ADVENT Long-Term Outcomes clinical trials for key devices like WATCHMAN FLX, EKOS, and FARAPULSE.

• Regulatory Approvals and Acquisition

  Received NMPA approval in China for the OPAL HDx™ Mapping System and U.S. FDA 510(k) clearance for the Asurys™ Fluid Management System. The acquisition of Valencia Technologies Corporation was also completed.

auto_awesomeAnalysis

Boston Scientific delivered a strong first quarter, meeting the high end of its adjusted EPS guidance and achieving robust sales growth. The company also provided updated full-year and new second-quarter guidance, which aligns with market expectations. Beyond financials, the filing highlights significant progress in its product pipeline with multiple positive clinical trial results and regulatory approvals, alongside a completed acquisition. These operational achievements, coupled with new board appointments, demonstrate solid execution and strategic advancement, which could be particularly impactful as the stock trades near its 52-week low.